Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 19/20 | 0.46 |
| ▸ | AURKA | O14965 | 15/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054649 | 0.88 | AURKB (0.49) | AURKBAURKAABL1BCRSRC | |
| SCHEMBL13054650 | 0.84 | AURKB (0.48) | AURKBAURKAABL1BCRSRC | |
| SCHEMBL13054657 | 0.84 | AURKB (0.44) | AURKBAURKAABL1BCRSRC | |
| SCHEMBL12430844 | 0.82 | AURKB (0.70) | AURKBAURKAABL1BCRSRC | |
| SCHEMBL13054652 | 0.79 | AURKA (0.51) | AURKBAURKAABL1BCRSRC | |
| SCHEMBL13054701 | 0.78 | AURKB (0.45) | AURKBAURKAABL1BCRSRC | |
| SCHEMBL13054631 | 0.78 | AURKA (0.59) | AURKBAURKASRCGSK3B | |
| SCHEMBL13054617 | 0.77 | AURKA (0.51) | AURKBAURKASRCGSK3B | |
| SCHEMBL13054659 | 0.76 | AURKB (0.41) | AURKBAURKAABL1BCRSRC | |
| SCHEMBL13054705 | 0.76 | AURKB (0.44) | AURKBAURKASRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | AURKB 18/4885AURKA 10/4885ABL1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.